Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics Q3 revenue rises to $211.0 million; net income $15.9 million

Positive Impact 3 of 5 earnings Written later

PTC Therapeutics reported third-quarter 2025 total revenue of $211.0 million, up from $196.8 million a year earlier, and net income of $15.9 million, compared with a net loss of $106.7 million in the same period of 2024. The company narrowed its full-year 2025 total revenue guidance to $750 million to $800 million and said the Sephience launch began in the US and Europe, though net product revenue for Translarna and Emflaza declined year over year.

Key points

  • Q3 2025 total revenue was $211.0 million, compared with $196.8 million in Q3 2024.
  • Q3 2025 net income was $15.9 million, or $0.20 per diluted share, versus a net loss of $106.7 million in Q3 2024.
  • Sephience generated $19.6 million in Q3 2025 global revenue, with 521 US patient start forms as of September 30, 2025.
  • Translarna net product revenue fell to $50.7 million from $72.3 million, and Emflaza fell to $35.2 million from $51.9 million.

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECNov 4, 2025, 4:10 PM ET
Accession number0001070081-25-000026

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.